Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia

• Published in: Schizophrenia Research and Treatment Vol. 2018; no. 2018; pp. 1 - 8
• Main Authors: Katshu, Mohammad Zia Ul Haq, Nizamie, S. Haque, Sarkar, Sukanto
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc; Hindawi Limited; Wiley
• Subjects: Age; Anesthesia; Antipsychotics; Care and treatment; Drug dosages; Drug therapy; Eye movements; Medical research; Medicine, Experimental; Mental depression; Neurosciences; Olanzapine; Psychopathology; Psychotropic drugs; Schizophrenia; Sleep apnea; Sleep disorders; Sociodemographics; Statistical analysis; Studies; India
• ISSN: 2090-2085; 2090-2093
• DOI: 10.1155/2018/3968015

Acute and short-term administration of olanzapine has a favorable effect on sleep in schizophrenia patients. This study aimed to clarify the effect of olanzapine on polysomnographic profiles of schizophrenia patients during the acute phase of illness after controlling for previous drug exposure. Twenty-five drug-naïve or drug-free schizophrenia patients were assessed at baseline and after six weeks of olanzapine treatment on Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS), and Udvalg for Kliniske Undersogelser (UKU) side-effect rating scale and a whole-night polysomnography; fifteen patients completed the study. There was a significant reduction in all psychopathological variables with maximum reduction in PANSS total, BPRS total, and PANSS positive scores. A significant increase in total sleep time (TST), sleep efficiency (SE), nonrapid eye movement (NREM) stage 1 duration, stage 3 duration, stage 4 duration, and stage 4 percentage of TST, number of rapid eye movement (REM) periods, REM duration, and REM percentage of TST was observed. REM latency at baseline inversely predicted the reduction in BPRS total and PANSS total and positive scores. In summary, short-term treatment with olanzapine produced significant improvement in clinical and polysomnography profiles of patients with schizophrenia with shorter REM latency predicting a good clinical response.